ProtaGene

Executive Summary

ProtaGene is a world-leading contract research organization (CRO) specializing in advanced protein and gene analytics for the biopharmaceutical and gene and cell therapy industries. Founded in 2001 and headquartered in Göttingen, Germany, the company provides integrated analytical packages that support biologic therapeutics from research through commercialization. With a focus on proteomics and genomics, ProtaGene serves as a critical partner for drug developers requiring rigorous characterization and quality control of complex biologics. The company's long-standing presence in the market and its comprehensive service offerings position it as a reliable player in the CRO space, although it operates in a highly competitive and rapidly evolving sector. Looking ahead, ProtaGene's growth is likely driven by the expanding gene and cell therapy market, which demands specialized analytical expertise. As a private pre-clinical company, it may seek strategic partnerships or funding to scale its capabilities. The company's ability to secure new contracts with emerging biotechs and established pharma will be key to its trajectory. While financial details are limited, its niche focus and established reputation provide a solid foundation for continued relevance in the biopharma analytics ecosystem.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership with a top-20 biopharma company for gene therapy analytics40% success
• Q2 2027Launch of new service package for cell therapy product characterization60% success
• H1 2027Disclosure of funding round to expand US presence55% success